|
AU2199901A
|
|
The treatment of convulsive states
|
|
AU7546500A
|
|
Designing immunogens
|
|
GB0019061D0
|
|
The treatment of convulsive states
|
|
GB0007789D0
|
|
Designing immunogens
|
|
GB9929981D0
|
|
The treatment of convulsive states
|
|
GB9923902D0
|
|
T-helper cell responses to proteins
|
|
GB9913458D0
|
|
The therapeutic use of d-threo-methylphenidate
|
|
US6162433A
|
|
Non antibiotic selectable markers for live vaccines
|
|
CA2304948A1
|
|
Pharmaceutical composition for the treatment of inflammatory bowel disease
|
|
AU7847098A
|
|
The preparation of enantiomerically-enriched threo- methylphenidate
|
|
GB9726233D0
|
|
Vaccines containing attenuated bacteria
|
|
GB9725346D0
|
|
Pharmaceutical composition for the treatment of inflammatory bowel disease
|
|
GB9725084D0
|
|
Vaccine compositions
|
|
GB9716242D0
|
|
Removal of endotoxin from vaccines
|
|
GB9712298D0
|
|
Crystallisation
|
|
GB9705740D0
|
|
A method of preservation
|
|
AU2102497A
|
|
Resolution of threo-methylphenidate
|
|
AU1608297A
|
|
Process for the preparation of D-threo-(R,R)-methyl phenidate and recycling of undesired enantiomers by epimerisation
|
|
HU9900798A2
|
|
Optical resolution of methylphenidate by o,o'-bisaroyl tartaric acids
|
|
ZA9700315B
|
|
Sustained-release formulation of methylphenidate.
|
